Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis

NCT01975610 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01975610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01975610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2013
Completion date
February 29, 2016
Enrollment
47 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis